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Abstract
Selective COX-2 inhibitors reduce adenoma formation
and cancer progression in rodent models of colorectal
cancer. To assess the therapeutic activity of selective
COX-2 inhibitors, we tested the effect of SC-58125
treatment on the growth of human colon carcinoma cells
in nude mice. Delaying treatment by 2, 4, or 7 weeks
following implantation of the carcinoma cells resulted in
a significant inhibition of tumor growth. Furthermore,
short - term (48 hours) treatment with SC-58125 was
sufficient to attenuate tumor growth for up to 15 days.
SC-58125 treatment did not alter the rate at which cells
underwent apoptosis, but did result in a delayed
progression through the cell cycle at the G2/M transi-
tion. Accordingly, p34cdc2 protein levels and activity
were decreased following SC-58125 treatment. We
conclude that SC-58125 primarily exerts a cytostatic
effect in vivo, which is likely to be mediated through
inhibition of progression through the G2/M phase of the
cell cycle. Neoplasia (2001) 3, 428–436.
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Introduction
Americans have a 1- in-20 lifetime risk of developing
colorectal cancer [4 ]. This disease is often detected at a
late stage when treatment is costly and the clinical outcome
is poor. Development of better prevention and therapeutic
strategies is critical to improve the prognosis for patients with
colorectal cancer. Non-steroidal anti - inflammatory drugs
(NSAIDs) represent one class of chemopreventive agents,
which have activity against colorectal cancer. Numerous
epidemiologic, animal, and clinical studies have shown that
NSAIDs reduce the risk of colorectal cancer [7,8,16,26].
Sulindac sulfide is a non-selective cyclooxygenase inhibitor
( IC50 ratio COX-1/COX-2=0.258) [28] and has been
shown to reduce adenoma number in rodent models of
intestinal cancer such as the Min mouse and the azoxy-
methane (AOM)- treated rat [2,18]. Sulindac has also been
shown to reduce the size and number of polyps in patients
with Familial Adenomatous Polyposis [7 ]. One known target
for this class of drugs is the cyclooxygenase enzyme. There
are two isoforms of this enzyme, cyclooxygenase-1 (COX-
1) and cyclooxygenase-2 (COX-2), which are key enzymes
for the production of prostaglandins. COX-1 is constitutively
expressed at low levels in many tissues, and it is believed that
inhibition of COX-1 leads to the pro-ulcerogenic effect seen
after prolonged NSAID use in humans [19]. COX-2 is
constitutively expressed in some organs ( i.e., brain and
kidney); however, this isoform is rapidly and transiently
induced by a variety of stimuli in numerous tissues and cell
types. COX-2 is not expressed in the normal colon or small
bowel; however, early neoplastic lesions constitutively
express this isoform [6].
Selective inhibition of COX-2 blocks growth of human
colon carcinoma xenografts in mice and carcinogen-
induced colon tumors in rats [9,11,17,20]. The hypothesis
that COX-2 is causally related to colorectal carcinogenesis
was evaluated using a genetic mouse model for colorectal
cancer. Oshima et al. [14] found that when adenomatous
polyposis coli (APC716) mutant mice were bred onto a
COX-2–deficient background, the tumor multiplicity was
reduced by nine- fold. Additionally, APC716 mutant mice
treated with a selective COX-2 inhibitor showed a marked
reduction in tumor number as well. Therefore, treatment
with a selective COX-2 inhibitor can have an effect at early
stages in the development of intestinal cancer; however,
the efficacy of treating established colorectal carcinomas
with selective COX-2 inhibitors has not been thoroughly
evaluated.
In the experiments described here, we test the hypothesis
that treatment with a selective (SC-58125) or non-selective
(sulindac sulfide) COX-2 inhibitor could alter the growth of
pre-existing carcinomas. We found that treatment with SC-
58125 blocked the growth of carcinoma cells by causing a
delay in the transition through the G2/M phase of the cell
cycle with a reduction in p34cdc2 levels. This work demon-
strates that SC-58125 effectively inhibits the growth of
established tumors. Hopefully, these results will stimulate
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further research aimed at understanding the potential role of
COX-2–selective inhibitors in cancer therapy.
Materials and Methods
Cell Culture
HCA-7 cells (a generous gift from Sue Kirkland) were
derived from a human rectal cancer. Lewis lung carcinoma
(LLC) cells were originally derived from a spontaneous lung
carcinoma in a C57/BL6 mouse and were purchased from
the American Type Culture Collection (CRL-1642; ATCC,
Manassas, VA). Both cell lines were maintained in Dulbec-
co’s modified Eagle’s media (DMEM; Gibco BRL Gaithers-
burg, MD) containing 10% fetal bovine serum (Hyclone
Laboratories, Ogden, UT), 100 U/ml penicillin, and 100 g/
ml streptomycin (1% Pen/Strep; Gibco BRL).
Xenograft Tumor Growth
HCA-7 cells were grown on plastic culture dishes
according to standard cell culture techniques [20]. The cells
were trypsinized, resuspended in sterile phosphate-buffered
saline (PBS), and then pelleted by brief centrifugation at
1800 rpm. The supernatant was aspirated and cells
resuspended in sterile PBS and counted manually using a
hemocytometer. Cells were resuspended in PBS to a final
concentration of 5107 cells /ml, and 100 l of cell
suspension was injected subcutaneously into the dorsal
flank of athymic mice (Harlan Sprague–Dawley, Indian-
apolis, IN) using a 27-gauge needle. The size of the tumor
was determined at 1-week intervals by direct measurement
of tumor dimensions. SC-58125 was dissolved in DMSO
and injected intraperitoneally at a dose of 10 mg/kg. Tumor
volume was determined by external measurement and
calculated according to the equation (V=[LW2 ]0.5),
where V=volume, L=length, and W=width [27].
Prostaglandin Measurements
Tumor PGE2 levels were measured using GC mass
spectroscopy as previously described [20]. The limit of
sensitivity for detection of PGE2 is 4 pg/ml.
Immunoblotting
Western blot analysis of protein lysates was performed as
previously described [5]. Briefly, cells were lysed for 30
minutes in RIPA buffer (1 PBS, 1% Nonidet P40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS],
10 mg/ml), then clarified cell lysates (100 g), and were
denatured and fractionated by 10% SDS-PAGE. After
electrophoresis, the proteins were transferred to PVDF
filters. The filters were blocked for 3 hours in Blotto (0.15
MNaCl, 10 mM Tris–HCl, pH 7.4, 0.1% Tween-20, 5% non-
fat dry milk ), and then incubated overnight with either COX-1
(N-20 SC-1753; Santa Cruz Biotechnology, Santa Cruz,
CA), COX-2 (N-20 SC-1746; Santa Cruz Biotechnology),
or p34cdc2 (17 SC-54; Santa Cruz Biotechnology)-specific
antibodies. The membranes were washed in TBST (0.15 M
NaCl, 10 mM Tris–HCl, pH 7.4, 0.1% Tween-20). The
membranes were then incubated with an HRP-conjugated
donkey antigoat secondary antibody for 45 minutes, then
washed three times, 15 minutes each with TBST before
processing using the ECL chemiluminescence system
(Amersham, Arlington Heights, IL) and exposed to XAR-5
film (Kodak, New Haven, CT).
Apoptosis Measurements
In the xenograft experiments, apoptotic cells were
identified in vivo as scattered single cells with a condensed
cytoplasm and either a pyknotic or fragmented nucleus.
Apoptotic cells in 10 high-power fields (400) were counted
24 hours after the last SC-58125 treatment, and the mean
number of apoptotic cells per high-power field was calcu-
lated. Each slide was counted twice and, if more than a 10%
discrepancy in the mean number of apoptotic cells was
found, the slide was re-counted until two successive
measurements were within 10% agreement.
In all culture experiments, apoptosis was evaluated using
three independent methodologies: TUNEL assay, DNA
laddering, and Annexin V staining. TUNEL assays were
performed using two separate systems: the in situ cell death
detection kit (POD; Boehringer Mannheim, Ridgefield, CT),
for evaluation of apoptotic cells in situ, and the APO-Direct
kit (Pharmingen, San Diego, CA), for quantitative evaluation
of apoptosis. For in situ apoptosis evaluation, HCA-7 or LLC
cells were grown on coverslips then treated with either 25,
50, or 100 M SC-58125 (G.D. Searle, St. Louis, MO) or an
equivalent volume of vehicle (DMSO). After drug treatment,
medium was discarded and the cells were washed and fixed
in 4% paraformaldehyde in PBS for 30 minutes at room
temperature (RT). Cells were incubated with 0.3% H2O2 in
methanol for 30 minutes at RT to block endogenous
peroxidase activity. The number of positive (apoptotic) cells
was analyzed by light microscopy. Flow cytometric detection
of fluorescein- labeled fragmented DNA was conducted to
quantitatively evaluate apoptosis in response to SC-58125
treatment. LLC or HCA-7 cells were seeded in 100-mm
plates and, when 80% confluent, they were treated with
DMSO or 100 MSC-58125. Negative control cells were not
treated and positive control cells were treated with 50 M
SC-58635 for 24 hours. Cells were harvested at 12 and 24
hours, washed in PBS two times, then fixed in 1%
paraformaldehyde for 15 minutes and permeabilized by
addition of ice-cold 70% ethanol. The APO-DIRECT kit was
used to end- label fragmented DNA with FITC-conjugated
dUTP as substrate. The labeling reaction was performed
according to the manufacturer’s recommendations with the
exception that 3106 cells per condition were used. After
labeling, cells were washed three times in PBS, then
resuspended in 1 ml propidium iodide (PI) staining solution
(5 g/ml PI, 40 g/ml RNASE A, in 1 PBS). Cells were
then filtered through 50-m mesh immediately prior to
analysis on a Becton Dickinson FACScan flow cytometer.
Gating on FL2 width was used to exclude aggregates, and
104 gated events were collected and analyzed.
Additionally, the ability of SC-58125 to induce apoptosis
was evaluated by testing for the presence of nucleosomal
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laddering of DNA. An equal number of cells were plated in
60-mm diameter culture dishes. At different times following
treatment with vehicle or SC-58125, attached and floating
cells were collected, centrifuged, and washed with PBS.
DNA was extracted using the PureGene purification kit
(Gentra Systems, Minneapolis, MN) according to the
manufacturer’s protocol. Tris phosphate EDTA (TPE)
agarose gels (1.5%) were prepared using multipurpose
agarose according to the manufacturer’s recommendations.
DNA samples were prepared in a neutral loading buffer
(0.25% bromophenol blue, 0.25% xylene cyanol, and 30%
glycerol in water ), and the DNA samples were electro-
phoresed and visualized by UV illumination.
In Vitro Proliferation Assays
The 3-(4,5-dimethylthiazol -2-yl -2,5-diphenyltetrazo-
lium bromide) (MTT) assay was employed to determine cell
viability /proliferation. This assay is a measure of mitochon-
drial activity; MTT is a yellow-colored tetrazolium salt that is
taken up and cleaved only by metabolically active cells,
reducing it to a colored, water - insoluble formazan salt. The
solubilized formazan product can be quantified via absorb-
ance at 570 nm measured using a 96 well - format spec-
trophotometer and the absorbance correlates directly with
cell number. Cells were seeded at 2104 cells /well in a 100
l volume in 96-well plates and grown for 24 hours in DMEM
supplemented with 10% FBS. The indicated amount of SC-
58125 or DMSO in 1% FBS containing OptiMEM media was
then added to the wells. At the indicated times, 10 l MTT (5
mg/ml) was added and the cells were incubated at 378C for
4 hours. The tetrazolium crystals were solubilized by addition
of 10% SDS in 0.01 N HCl. After overnight incubation at
378C, the optical density was measured at 570 nm using a
96-well spectrophotometric plate reader (Packard Instru-
ments, Meriden, CT). Results represent the mean±SD of six
wells from one experiment and are representative of experi-
ments repeated at least three times.
Flow Cytometric Analysis
After treatment with either DMSO (vehicle) or SC-58125,
HCA-7 cells were trypsinized at the indicated times with 500
l of 2 mg/ml trypsin /0.02% EDTA for 2 to 5 minutes,
scraped, and pelleted by centrifugation at 1000g for 5
minutes. Cell pellets were washed twice in PBS, then
pelleted and resuspended in 1 ml of PBS. Cells were
passaged through a 21-gauge needle 10 times to bring to a
single cell suspension. Lewis lung carcinoma cells are a
semi-adherent culture and did not require trypsinization or
needle passage to obtain single cell suspensions. The cells
were fixed by the addition of 1 ml of ice-cold 100% ethanol,
which was added dropwise while gently vortexing the
samples. An additional 1 ml of ethanol was then added and
the samples stored at 48C for at least 2 hours. Cells were
pelleted by centrifugation and washed one time in PBS and
then resuspended in PI staining solution (0.5 mg/ml RNase
A, 20 g/ml PI, in PBS). Samples were stored at RT for 30
minutes then filtered through 50-m filters to remove
aggregates immediately prior to analysis. Flow cytometric
analysis was performed using a FACScan cytometer
(Becton Dickinson, San Jose, CA). Single cell populations
were gated using forward scatter, an indicator of cell size
versus side scatter, an indicator of cell granularity. The FL2
detector measures fluorescent light from PI, and PI intensity
is proportional to the DNA content of the cell. The FL2-PI
area versus width plots distinguished true cycling G2/M cells
from doublets or aggregates of G0/G1 cells by comparison to
standardized area versuswidth plots and were adjusted in all
experiments. Cell Quest Software (Becton and Dickinson
Immunocytometry System) was used to control the collec-
tion of data from at least 10,000 cells per sample at low flow
rate (12 l /min), and DNA data were analyzed with ModFit
software (Verity Software House, Popsham, ME).
Dual parameter flow cytometry was used to assess the
effect of SC-58125 on the proliferation rate of LLC cells.
Cells were plated and allowed to attach for 24 hours then
pulsed for 45 minutes with 10 M BrdU ( In Situ Cell
Proliferation Kit, FLOUS; Boehringer Mannheim). Cells were
washed two times in PBS and growth media were replaced
with OptiMEM media (Gibco BRL) supplemented with 1%
FBS with either vehicle (DMSO) or the indicated amount of
SC-58125. Cells were treated for the indicated times then
harvested either by trypsinization, as described above for the
HCA-7 cells, or by gentle washing with media (LLC cells ).
Cells were fixed and prepared as described by Becton
Dickinson’s dual parameter BrdU/PI protocol. An isotype-
matched ( IgG2) FITC-conjugated control antibody was used
to determine and adjust for background FITC fluorescence.
Cells were filtered through a 50-m mesh filter and then
10,000 gated events were collected using a Becton Dick-
inson FACScan flow cytometer. Analysis was performed
using FlowJo (TreeStar, Palo Alto, CA).
Mitotic Figure Determination
Mitotic cells were identified by assessing nuclear changes
using the nuclear binding dye 40,6 -diamidino-2-phenyl-
indole (DAPI) dihydrochloride and fluorescence microscopy.
Ten high-power fields were counted per condition and the
average is presented ±SD. After 12 hours of treatment, the
cells were fixed, the number of mitotic figures per high power
field was counted, and a mitotic index was calculated.
Differential Gene Expression
Total RNA was isolated from vehicle and SC-58125–
treated cells using the Tri -Reagent extraction method (MRC
Research, Cincinatti, OH). Total RNA (5 g) was primed
with oligo dT (Research Genetics, Huntsville, AL), and
reverse- transcribed with Superscript II RT (Gibco BRL) in
the presence of [33P]dCTP (ICN, Costa Mesa, CA). The
resultant probes were hybridized to cDNA microarrayed onto
a nylon membrane (GENEFILTERS release 200; Research
Genetics) for 16 hours. After washing, the membrane was
exposed to a phosphorimage screen (Cyclone Storage
Phosphor System; Packard Instruments). Images were
imported into the PATHWAYS analysis program (Research
Genetics) and analyzed for differential gene expression.
Differential expression was confirmed by Northern blotting of
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total RNA (20 g), which was separated on formaldehyde
agarose gels and blotted onto nitrocellulose filters. A probe
was generated by random primer extension using
[32P ]dCTP of a cDNA fragment derived from the 30 UTR
of human p34cdc2. Blots were washed then imaged using the
Cyclone phosphorimaging system (Packard Instruments).
Statistical Methods
The significance of the effect of treatment on xenograft
growth was determined using repeated measures ANOVA
and the Statview analysis package (SAS Institute, Cary,
NC). The Students’ t - test was employed to compare the
difference in means between various groups.
Results
SC-58125 Treatment of Established Colorectal Carcinoma
Xenografts
We have previously reported that HCA-7 xenograft
growth was attenuated when mice were treated with SC-
58125 at the time of tumor engraftment [20]. In order to
evaluate the effectiveness of SC-58125 at inhibiting
established HCA-7 xenograft growth, mice were treated at
the time of tumor implantation or 2 and 4 weeks later.
Vehicle- treated mice exhibited a tumor volume doubling
time of 2.6 weeks (Figure 1A ). We observed a statistically
significant decrease in the tumor growth rates in all of the
SC-58125–treated mice when compared to controls
(P<.0001). Inhibition of xenograft growth was evident within
1 week following initiation of treatment. Therefore, SC-
58125 treatment of established tumors resulted in attenu-
ation of tumor growth.
We next sought to compare the effect of a non-selective
COX inhibitor, sulindac sulfide, and a COX-2–selective
inhibitor, SC-58125, on xenograft growth. HCA-7 cells were
implanted into nude mice and, at 7 weeks following
implantation, the mice were divided into three groups: 1)
control, 2) SC-58125, or 3) sulindac sulfide. Both SC-58125
Figure 1. SC-58125 treatment inhibits the growth of established colorectal
cancer xenografts. (A ) 5106 HCA -7 cells were xenografted into the dorsal
flank of 26 nude mice. Animals were treated every 48 hours with either DMSO
(square ) or SC -58125 (10 mg / kg ) at the time of cell injection ( circle ), or 2
weeks ( triangle ) or 4 weeks after intraperitoneal injection (diamond ). (B )
5106 HCA -7 cells were xenografted into the dorsal flank of nude mice. SC -
58125 (10 mg /kg, circle ), sulindac sulfide ( 10 mg /kg, triangle ), or DMSO
(square ) injections were delayed until week 7. (B, insert ) HCA -7 cells were
implanted as noted above, then after 1 week of growth, only two injections of
SC -58125 (10 mg / kg ) were given intraperitoneally at 48 - hour intervals.
Tumor volumes were determined by external measurement on a weekly basis
and calculated using the equation (V= [ LW2 ]0.5 ), where V=volume,
L= length, and W=width [ 27 ].
Figure 2. SC-58125 reduces tumor PGE2 levels. In order to determine the
efficacy of SC -58125 treatment, the PGE2 concentrations were monitored in
the tumor. Mice were sacrificed at 2, 4, 6, 12, 24, 36, and 48 hours following
SC-58125 treatment ( 10 mg / kg ). Tumors were excised and flash - frozen in
liquid nitrogen. PGE2 levels were determined by gas chromatograph mass
spectroscopy and expressed as ng PGE2 /pg protein.
Figure 3. The tumor levels of COX -1 and COX-2 protein do not change with
SC-58125 treatment. HCA -7 tumor - bearing mice were injected with SC-
58125 (10 mg /kg ) and sacrificed at 2, 4, 6, 12, 24, 36, and 48 hours after SC -
58125 treatment. Fifty micrograms of tumor lysate was resolved by SDS-
PAGE then transferred to a membrane. COX -1– or COX -2–specific goat
antisera were used at 1:1000 and 1:500, respectively.
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and sulindac sulfide treatment inhibited xenograft growth to
the same extent (Figure 1B ).
The effectiveness of short - term SC-58125 treatment on
tumor growth was then evaluated. HCA-7 xenografts were
implanted and, after 1 week, SC-58125 was given once per
day for 2 days and then discontinued. To our surprise,
xenograft growth was arrested by this treatment strategy
(Figure 1B, insert ). However, by day 18 following this
transient treatment regimen, the tumors had returned to
control growth rates. To determine the effect of SC-58125
on tumor prostaglandin levels, PGE2 was measured at 2, 4,
6, 12, 24, 36, and 48 hours following SC-58125 treatment
(Figure 2 ). A significant reduction in PGE2 was observed
within 2 hours of treatment with maximal inhibition occurring
at 12 hours. PGE2 levels remained low for 24 hours and then
began to increase, reaching 50% of initial levels within 36
hours following treatment. Therefore, SC-58125 effectively
inhibited prostaglandin synthesis in the xenografted carci-
nomas, indicating that the drug was well distributed to the
tumor site.
It has been reported that treatment of cells with non-
selective NSAIDs can alter the expression of COX-2 [12]. It
is possible that the decrease in PGE2 levels shown in Figure
2 may be due, in part, to alterations in the levels of COX-2.
To evaluate this possibility, we extracted protein from the
tumors and measured COX-1 or COX-2 levels in the
xenografted carcinomas byWestern blot analysis (Figure 3 ).
There was no detectable COX-1 protein in HCA-7 xeno-
grafts; however, COX-2 was present and its level did not
change following SC-58125 treatment. Therefore, since
COX-1 was not detected and COX-2 levels did not change,
Figure 4. SC-58125 inhibits the in vitro growth of HCA -7 and LLC cells. (A )
Phase contrast photomicrographs of HCA-7 cells treated for 3 days with 100
M SC-58125 (SC-58125 ) or DMSO (Vehicle ) (200 ). (B ) HCA -7 and
LLC cells treated with the indicated amount of SC -58125 for 3 days. Viability
assay (MTT ) for HCA -7 and LLC cells. Each data point represents the mean
of six replicates; error bars represent ±SD. (C ) Cells treated as in (B ) were
counted in triplicate using a Coulter counter. Error bars represent ±SD.
Figure 5. SC-58125 does not induce apoptosis. LLC (A ) or HCA -7 (B ) cells
untreated ( negative control ), treated with SC -58635 (positive control ),
DMSO (vehicle ), or with 100 M SC-58125 for 24 hours ( LLC ), or 72 hours
(HCA-7 ). Cells were harvested then fixed, and fragmented DNA was labeled
using the TUNEL assay with dUTP -FITC as substrate. Analysis was
performed using a Becton Dickinson FACScan flow cytometer. Ten thousand
gated events were analyzed.
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it is most likely that the decrease in PGE2 is due to inhibition
of COX-2 activity by SC-58125.
Hypothetically, SC-58125 treatment could cause a
reduction in tumor size by decreasing proliferation and/or
increasing apoptosis rates within the tumor. To determine if
SC-58125 treatment increased the number of cells under-
going programmed cell death, apoptotic figures from
hematoxylin- and eosin-stained sections from control and
SC-58125 tumors were counted and compared. No signifi-
cant difference in the number of apoptotic cells was observed
(Table 1).
In summary, we demonstrate that SC-58125 treatment
inhibits the growth of established tumors and that as few as
two treatments significantly attenuate tumor growth. SC-
58125 did not have a significant effect on the rate of cells
undergoing apoptosis in vivo asmeasured by apoptotic index
of SC-58125–treated xenografts. This result was surprising
since other NSAIDs have been shown to stimulate carci-
noma cell to undergo apoptotic cell death. Growth inhibition
was associated with a reduction in PGE2 production without
any change in the level of COX-2 protein.
Proliferation Assays
To determine the effect of SC-58125 on the growth of
carcinoma cells, we studied both the HCA-7 and LLC cells.
COX-1 and COX-2 are expressed constitutively at high
levels in the LLC cells. SC-58125 was not toxic to these cells
even when treated for up to 3 days at 100 M dose (Figure
4A ) and no change in cell viability was seen as determined
by trypan blue exclusion (data not shown). We measured
both cell counts (Figure 4B ) and MTT activity (Figure 4C ) to
evaluate the effect of SC-58125 treatment on cell growth.
The MTT assay provides a measure of cell viability because
conversion of the MTT substrate to formazan crystals
requires intact and functional mitochondria. We observed
Figure 6. SC-58125 induces G2 arrest in LLC cells. (A ) Cell cycle profile of
LLC cells treated for 12 hours with either (1: Control ) DMSO or ( 2: SC -
58125 ) 100 MSC-58125. Cells were harvested and processed as described
in Materials and Methods section prior to performing flow cytometric analysis.
(B ) SC-58125 time course (panel 1 ) and SC-58125 dose response of LLC
cells ( panel 2 ). Fractional representation of cells in the G2 phase of the cell
cycle. (C ) LLC cells were treated for 12 hours with 100 M SC-58125, 100
M sulindac sulfide, or DMSO (Vehicle ). Sulindac sulfide induces a G1 arrest,
which is followed by apoptosis. Cells were fixed and stained with DAPI a DNA
chromophore. Nuclei were visualized using a fluorescent microscope. Mitotic
figures were counted per high - power field. Ten high - power fields per
treatment were counted and the mean calculated. Error bars represent ±SD.
Figure 7. SC-58125 reduces the proliferation rate of LLC and HCA-7 cells.
(A ) LLC cells were pulsed with 10 M BrdU for 30 minutes then washed 2 in
PBS prior to switching to vehicle (DMSO, Control ) or SC -58125–containing
media ( 100 M, SC-58125 ). Twelve hours later, the cells were fixed and
processed for dual parameter flow cytometry. BrdU -FITC content is shown on
the ordinate and PI measured DNA content on the abscissa. (B ) Cells were
treated as in (A ) then samples were obtained at the indicated time points. The
percent of G1 BrdU - labeled cells for control and SC -58125– treated cells was
calculated. The G1 ratio (Control /SC -58125 ) is shown on the y -axis, and the
x -axis indicates the time of treatment. LLC: black bars, HCA -7: gray bars.
Table 1. Apoptotic Figure Counts in HCA-7 Xenografts.
Treatment Count (Per HPF* ) P Valuey
Control 566.5 –
SC-58125 666.8 0.55
Sulindac sulfide 452.0 .23
*HPF, high - power field (400 ).
yStudent’s unpaired t - test.
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an SC-58125 dose-dependent reduction in cell number and
MTT activity in both cell lines (Figure 4B and C ); however,
LLC cells were more sensitive than HCA-7 cells to treatment
with SC-58125. We determined that the effect of treatment
on the number of cells undergoing programmed cell death
was not significant using the TUNEL assay (Figure 5 ), DNA
laddering (data not shown), and annexin V staining (data not
shown).
Effect of SC-58125 Treatment on Cell Cycle Distribution
We next examined the effect of SC-58125 on LLC cell
cycle distribution using flow cytometry. We observed a
profound dose- and time-dependent increase in the number
of cells containing 4n DNA content following treatment with
SC-58125 (Figure 6A and B ). An increase in 4n DNA
content was found as early as 4 hours after treatment with
doses as low as 25 M. To determine if this was due to a
mitotic block, LLC cells were treated with SC-58125 or
sulindac sulfide and the mitotic indices were calculated.
There was a significant reduction in the number of mitotic
figures in the SC-58125–treated cells, indicating that the
increase in 4n DNA content was due to a late S- or G2-
phase block (Figure 6C ). Interestingly, when similar experi-
ments were performed on the HCA-7 cells, an increase in 4n
DNA content was not observed. However, there was an
increase in the S-phase assigned fraction (data not shown).
This result may be due to technical problems associated with
HCA-7 cell preparation for cell flow analysis because the
adherence properties of HCA-7 cells make it difficult to
obtain pure single cell suspensions.
To directly test the effect of SC-58125 on cell prolifer-
ation, we pulse- labeled HCA-7 and LLC cells with BrdU and
then added SC-58125 to the medium. In the LLC cells, 12
hours of treatment with SC-58125 resulted in an increase in
the number of cells in late S/G2 with virtually no labeled cells
reaching the mitotic phase of the cell cycle (Figure 7A ).
Interestingly, 18 hours following treatment, this G2/M arrest
was partially overcome, indicating an incomplete block
(Figure 7B ). A similar effect was observed in the HCA-7
cells, though to a lesser degree, which correlates with the
reduced sensitivity of HCA-7 cells to SC-58125. At 12 hours
following treatment, there was a 2.5- fold reduction in the
Figure 8. p34cdc2 levels are decreased by SC-58125 treatment. HCA-7 cells were plated and treated with 0, 25, 50, or 100 M SC-58125 for 3 days. (A ) Northern
blot using a [ 32P ] - labeled p34cdc2 cDNA probe. The numbers below the panel show the fold reduction in p34cdc2 levels as quantified by phosphorimage analysis. (B )
p34cdc2 Northern blot of total RNA extracted from HCA-7 xenograft tumors. After 8 weeks of tumor growth, animals were divided into two groups; each group
received either SC -58125 or DMSO injections every other day for 1 week. (C ) p34cdc2 protein levels in HCA -7 cells treated with SC-58125 at the indicated dose.
Whole cell lysates were obtained after 3 days of treatment. Fifty micrograms of lysate was electrophoresed then transferred to nylon membranes and blotted with
p34cdc2 - specific antisera. ( + ) Positive control for p34cdc2. (D ) In vitro H1 kinase assay. HCA -7 cell lysates were generated from cells treated for 3 days with SC -
58125 of vehicle. Kinase activity was measured as previously described [ 23 ].
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fraction of labeled cells transiting into G1, and a partial
escape was observed by 24 hours. We conclude from these
studies that the primary effect of SC-58125 treatment on
both LLC and HCA-7 cells is to inhibit cell proliferation.
Molecular Targets
High-density expression arrays were screened to determine
if the expression of growth-regulating genes is affected by
SC-58125 treatment of HCA-7 cells. The filter gene arrays
were hybridized with [32P]- labeled cDNA reverse- tran-
scribed from mRNA isolated from either SC-58125– or
DMSO-treated HCA-7 cells. The expression levels of a
number of genes were affected following treatment with SC-
58125, and of particular interest to this study, the levels of
p34cdc2 mRNA were reduced in a dose-dependent fashion
following SC-58125 treatment with 100 M SC-58125
resulted in a three- fold decrease in p34cdc2 mRNA (Figure
8A ). There are two splice variant forms of p34cdc2 mRNA
present (Figure 8A ), which have been previously reported
[25]. SC-58125 treatment also reduced p34cdc2 mRNA
(Figure 8B ) and protein (Figure 8C ) levels in HCA-7
xenografts as well. Histone H1 kinase is a substrate for
p34cdc2. To determine whether SC-58125 modulated
p34cdc2 kinase activity, p34cdc2 was immunoprecipitated
from SC-58125–treated and control HCA-7 cells and then
phosphorylation levels of histone H1-kinase by p34cdc2 were
determined. We found that SC-58125 treatment resulted in a
dose-dependent decrease in kinase activity with strong
inhibition, even at the lowest concentration of SC-58125
(Figure 8D ). It is possible that the reduction in p34cdc2 levels
and activity following SC-58125 treatment may contribute to
inhibition of cell proliferation.
Discussion
We have previously reported that treatment with SC-58125
inhibits the growth of colorectal cancer xenografts [20]. In
those experiments, treatment was initiated at the time of
tumor implantation and by starting treatment this early, the
key effect could be primarily due to a reduction in graft
attachment and survival. We also reported that SC-58125
treatment of cultured cells may result in a slight increase in
apoptosis [21]. Therefore, we decided to evaluate the effect
of SC-58125 on the growth of already established tumors in
vivo. We found that when treatment was delayed either 2, 4,
or 7 weeks after carcinoma cell implantation, that xenograft
growth was significantly attenuated. Interestingly, delayed
treatment resulted only in a cytostatic effect and neither SC-
58125 nor sulindac sulfide led to tumor regression. In rodent
models of colorectal cancer, where predisposition to cancer
development can be increased by either genetic manipu-
lation or carcinogen treatment, both selective and non-
selective NSAIDs decrease tumor burden as well as
stimulate regression of existing adenomas [1–3,11,13].
Treating mice with established colon carcinoma xenografts
may represent a more appropriate model in which to test
therapeutic potential for NSAIDs and selective COX-2
inhibitors. Our results suggest that SC-58125 treatment of
existing carcinomas is effective at inhibiting the expansion of
tumor mass. Due to the limited toxicity of selective COX-2
inhibitors, these compounds may be useful in combination
with existing chemotherapeutic drugs or ionizing radiation for
the treatment of patients with colorectal cancer.
The in vivo mechanism for action of SC-58125 has yet to
be determined. Hypothetically, this compound could inhibit
xenograft growth by inducing apoptosis, inhibiting prolifer-
ation, and/or by limiting a host-derived parameter such as
angiogenesis or enhancing immune responses to the
xenograft. It has recently been shown that LLC tumors
grown in COX-2 knockout animals exhibit reduced growth
rates then either wild - type and COX-2 heterozygote hosts.
Therefore, SC-58125 might inhibit tumor growth, at least in
part, by inhibiting host-derived COX-2. Sulindac sulfide has
been shown to induce apoptosis in colorectal cancer cell
lines in vitro and in adenomas in both the Min mouse and
AOM-treated rat [13,15,18]. We did not observe an increase
in apoptosis in sulindac sulfide–treated HCA-7 xenografts
as measured by comparison of the quantity of apoptotic
figures in control and SC-58125–treated tumors. In one of
our previous reports [21], we did observe a slight modulation
in the rate of cells undergoing apoptosis (0.7% increase) in
vitro following SC-58125 treatment. However, the effect of
SC-58125 treatment on cell proliferation was not evaluated
in that study and, in light of our current results, it seems more
likely that the predominant effect of SC-58125 on HCA-7
and LLC cells is inhibition of their progression through the cell
cycle.
SC-58125 inhibited the growth of both HCA-7 and LLC
cells grown in culture by delaying transit through the G2
phase of the cell cycle. Sulindac sulfide has been reported to
induce a G2 arrest in HCT-15 cells, followed by programmed
cell death [10]. We observed a reduction in p34cdc2 levels
and activity following SC-58125 treatment. p34cdc2 is a
cyclin-dependent kinase and a key regulator of the transition
of cells from the G2 to M phase of the cell cycle.
Downregulation of p34cdc2 and G1 arrest has been reported
following treatment of cells with non-selective NSAIDs
[22,24]. In the experiments reported by Shiff et al. [22,24],
NSAIDs such as sulindac, indomethacin, and aspirin caused
a downregulation of p34cdc2, but it is not clear how this effect
was related to the G1 arrest and resultant induction of
apoptosis. Our experimental results indicate that SC-58125
treatment led to an increase in the fraction of cells in the G2
phase of the cell cycle. BrdU labeling studies confirmed that
the block in G2 was incomplete. A decrease in p34
cdc2 levels
and activity may contribute to the delay in progression
through the cell cycle and the resultant decrease in
proliferation rate of both LLC and HCA-7 cells following
SC-58125 treatment.
In summary, we present evidence that treatment with SC-
58125, a selective COX-2 inhibitor, reduced the growth of
established colon carcinoma xenografts, resulting in tumor
cytostasis. Here, we employ gene array technology to
determine the alterations in carcinoma gene expression
following treatment. In cell culture studies, SC-58125 treat-
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ment inhibited proliferation and led to an accumulation of
cells in the G2 phase of the cell cycle with a reduction in
p34cdc2 levels. Further studies will be required to determine
whether other genes whose levels are altered by COX-2
inhibitor treatment may serve as useful intermediate markers
for future cancer prevention and/or treatment trials in
humans. Future studies may also be warranted in evaluating
treatment regimens for colorectal cancer, which specifically
target cells in specific phases of the cell cycle in combination
with a selective COX-2 inhibitor.
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